← Browse by Condition
Medical Condition

fallopian tube cancer

Total Trials
7
Recruiting Now
7
Trial Phases
Phase 1, Phase 3, Phase 2

Cancer clinical trials represent the largest single category of recruiting studies worldwide, encompassing everything from early-phase safety studies of novel oncology drugs to large Phase 3 comparisons against current standard-of-care chemotherapy regimens. The field has accelerated dramatically with the rise of immunotherapy, targeted therapies, and CAR-T cell treatments that have transformed outcomes for previously untreatable malignancies.

Trials include checkpoint inhibitors (PD-1/PD-L1 agents), KRAS inhibitors, ADC (antibody-drug conjugates), combination chemotherapy regimens, radiation protocols, and surgical technique comparisons. Many trials stratify by biomarker status (PD-L1 expression, TMB, MSI-H) to identify patients most likely to benefit.

The NCI, pharmaceutical sponsors, and academic cancer centers collectively fund thousands of oncology trials annually across every cancer type.

Frequently Asked Questions — fallopian tube cancer Clinical Trials

How many clinical trials are currently recruiting for fallopian tube cancer?
ClinicalMetric currently tracks 7 actively recruiting clinical trials for fallopian tube cancer, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 7. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for fallopian tube cancer?
fallopian tube cancer research spans Phase 1 (2 trials), Phase 2 (2 trials), Phase 3 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a fallopian tube cancer clinical trial?
Eligibility criteria for fallopian tube cancer trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1
2
Phase 2
2
Phase 3
1
Top Sponsors
Memorial Sloan Kettering Cancer Center 1 trial
Brigham and Women's Hospital 1 trial
Genelux Corporation 1 trial
North Eastern German Society of Gynaecological Oncology 1 trial
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 1 trial

Recruiting Clinical Trials

NCT05429970
Recruiting

A Study Comparing Perioperative Stress Reduction vs. Standard of Care in Ovarian Cancer (PRESERVE)

Enrollment
35 pts
Location
United States
Sponsor
Memorial Sloan Kettering Cance...
View Trial →
NCT04701645 Phase 1
Recruiting

Microdevice In Ovarian, Fallopian Tube, And Peritoneal Cancer

Enrollment
20 pts
Location
United States
Sponsor
Brigham and Women's Hospital
View Trial →
NCT05281471 Phase 3
Recruiting

Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

Enrollment
186 pts
Location
United States
Sponsor
Genelux Corporation
View Trial →
NCT05460000 Phase 2
Recruiting

A Phase II Randomized, Open Label Non-inferiority Study of NiraParib Maintenance After 3 vs. 6 Cycles of Platinum-based Chemotherapy in completeLy debUlked Advanced HRDpositive High-grade Ovarian Cancer patientS in First Line Therapy

Enrollment
640 pts
Location
Austria, Belgium, Cz...
Sponsor
North Eastern German Society o...
View Trial →
NCT06617923 Phase 2
Recruiting

Study of Senaparib in Combination With Temozolomide in ARID1A Mutation Associated Ovarian Cancer

Enrollment
18 pts
Location
United States
Sponsor
Sidney Kimmel Comprehensive Ca...
View Trial →
NCT04516447 Phase 1
Recruiting

A Study of Azenosertib (ZN-c3) in Patients With Ovarian Cancer

Enrollment
172 pts
Location
United States, Austr...
Sponsor
K-Group, Beta, Inc., a wholly ...
View Trial →
NCT06445621
Recruiting

Early Detection of Relapse in Ovarian Cancer Using Capillary Home-sampling and a Protein Biomarker Test

Enrollment
125 pts
Location
Sweden
Sponsor
Uppsala University Hospital
View Trial →
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology